Competition watchdog says HRT drug deal could raise prices
Theramex would buy the European rights to two drugs under a deal announced last year.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The competition watchdog has found that women needing hormone replacement therapy (HRT) might see higher prices if a deal between two businesses is allowed to go ahead.
The Competition and Markets Authority (CMA) said that an initial investigation had found that the plan for Theramex to buy the European rights to two drugs could reduce competition.
Last year, the London-based women’s health company said it would buy the rights to Duphaston and Femoston HRT from US company Viatris.
Theramex is already one of the largest players in the UK’s market for “systemic” HRT. Systemic HRT drugs treat the whole body, rather than just a localised area.
We’re concerned this deal between Theramex and Viatris, which transfers control of Femoston and Duphaston in the UK and Europe, may reduce competition and lead to higher prices
It supplies oestrogen patches as well as oestrogen and progestogen patches and pills.
“The CMA is concerned that the deal could reduce competition in this important market, the cost of which is often covered by the NHS, by reducing incentives to bring new products to the market and improve and promote existing products,” the watchdog said.
“The reduction of HRT alternatives in a market that is already highly concentrated could reduce choice and also lead to potential price increases, as well as raising concerns about the security of supply.”
The companies have five days to respond to the concerns with “meaningful solutions” or risk facing a phase 2 investigation from the watchdog.
Senior director for mergers Sorcha O’Carroll said: “HRT plays a critical role in treating symptoms which impact the everyday lives of millions of women.
“We’re concerned this deal between Theramex and Viatris, which transfers control of Femoston and Duphaston in the UK and Europe, may reduce competition and lead to higher prices, as well as preventing new treatments being brought to market.
“Our door is now open to the firms to offer solutions to our concerns, otherwise this case will proceed to a more in-depth investigation.”